150 related articles for article (PubMed ID: 33776702)
1. Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Ravindranathan D; Russler GA; Yantorni L; Drusbosky LM; Bilen MA
Case Rep Oncol; 2021; 14(1):190-196. PubMed ID: 33776702
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
3. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.
Yoshida T; Yaegashi H; Toriumi R; Kadomoto S; Iwamoto H; Izumi K; Kadono Y; Ikeda H; Mizokami A
Front Oncol; 2022; 12():912490. PubMed ID: 36185251
[TBL] [Abstract][Full Text] [Related]
4. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE; Lai M; Yu EY; Schweizer MT
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.
Fujiwara M; Komai Y; Yuasa T; Numao N; Yamamoto S; Fukui I; Yonese J
IJU Case Rep; 2020 Mar; 3(2):62-64. PubMed ID: 32743472
[TBL] [Abstract][Full Text] [Related]
7. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O; Tan W; Bryce AH; Dronca RS; Childs DS; Pagliaro LC; Orme JJ; Kase AM
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341460
[TBL] [Abstract][Full Text] [Related]
8. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.
Kageyama T; Soga N; Sekito S; Kato S; Ogura Y; Kojima T; Kanai M; Inoue T
IJU Case Rep; 2022 Nov; 5(6):442-445. PubMed ID: 36341181
[TBL] [Abstract][Full Text] [Related]
9. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
11. Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy.
Kasi PM; Afghan MK; Bellizzi AM; Chan CH
Cureus; 2022 Jul; 14(7):e26648. PubMed ID: 35815302
[TBL] [Abstract][Full Text] [Related]
12. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
[TBL] [Abstract][Full Text] [Related]
13. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing.
Anisetti B; Coston TW; Ahmed AK; Mahadevia HJ; Edgar MA; Starr JS; Babiker HM
Cureus; 2023 Apr; 15(4):e37239. PubMed ID: 37168199
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
15. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Kawaoka T; Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Hepatol Res; 2020 Jul; 50(7):885-888. PubMed ID: 32088930
[TBL] [Abstract][Full Text] [Related]
16. High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies.
Silveira AB; Bidard FC; Kasperek A; Melaabi S; Tanguy ML; Rodrigues M; Bataillon G; Cabel L; Buecher B; Pierga JY; Proudhon C; Stern MH
Clin Chem; 2020 Apr; 66(4):606-613. PubMed ID: 32176763
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
18. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
[TBL] [Abstract][Full Text] [Related]
19. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
Nakamura Y; Okamoto W; Denda T; Nishina T; Komatsu Y; Yuki S; Yasui H; Esaki T; Sunakawa Y; Ueno M; Shinozaki E; Matsuhashi N; Ohta T; Kato K; Ohtsubo K; Bando H; Hara H; Satoh T; Yamazaki K; Yamamoto Y; Okano N; Terazawa T; Kato T; Oki E; Tsuji A; Horita Y; Hamamoto Y; Kawazoe A; Nakajima H; Nomura S; Mitani R; Yuasa M; Akagi K; Yoshino T
JCO Precis Oncol; 2022 Feb; 6():e2100383. PubMed ID: 35188805
[TBL] [Abstract][Full Text] [Related]
20. [Experience of Pembrolizumab Administration in A Patient with Castration-Resistant Microsatellite Instability-High Prostate Cancer].
Takasawa T; Amano T; Himeno M; Imao T
Hinyokika Kiyo; 2024 Feb; 70(2):51-54. PubMed ID: 38447945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
